Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book, now in its third edition, examines the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the appropriate management in special clinical circumstances, including in the elderly, pregnant women, and those with nodular lymphocyte-predominant disease (NLPHL). Careful attention is devoted to the emerging individually tailored treatment strategies, including checkpoint inhibition, that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The new edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.

Hematology. --- Oncology  . --- Oncology. --- Tumors --- Haematology --- Internal medicine --- Blood --- Diseases --- Hodgkin's disease. --- Hodgkin disease --- Hodgkin lymphoma --- Hodgkin's lymphoma --- Lymphadenoma --- Lymphogranuloma --- Lymphogranulomatosis --- Lymphosarcoma --- Pseudoleucemia --- Lymphomas

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is a pocket guide to the practice of PET/CT imaging of Hodgkin’s lymphoma. The role of PET/CT in Hodgkin’s lymphoma, the characteristic findings and patterns, and the advantages and limitations of this hybrid modality are all clearly described. In addition, information is provided on clinical presentation, diagnosis, staging, pathology, management, and conventional radiological imaging. A useful pictorial atlas is included at the end of the book. PET/CT in Hodgkin’s Lymphoma is published within the Springer series Clinicians' Guides to Radionuclide Hybrid Imaging, which is aimed at referring clinicians, nuclear medicine/radiology physicians, radiographers/technologists, and nurses who routinely work in nuclear medicine and participate in multidisciplinary meetings. Compiled under the auspices of the British Nuclear Medicine Society, the series is the joint work of many colleagues and professionals worldwide who share a common vision and purpose in promoting and supporting nuclear medicine as an important imaging specialty for the diagnosis and management of oncological and non-oncological conditions.

Hodgkin's disease. --- Hodgkin disease --- Hodgkin lymphoma --- Hodgkin's lymphoma --- Lymphadenoma --- Lymphogranuloma --- Lymphogranulomatosis --- Lymphosarcoma --- Pseudoleucemia --- Medicine. --- Nuclear medicine. --- Oncology. --- Medicine & Public Health. --- Nuclear Medicine. --- Lymphomas --- Oncology  . --- Tumors --- Atomic medicine --- Radioisotopes in medicine --- Medical radiology --- Radioactive tracers --- Radioactivity --- Physiological effect

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed.

Medicine --- Oncology --- multiple myeloma --- venous thromboembolism --- risk assessment models --- thromboprophylaxis --- direct oral anticoagulants --- cancer-associated venous thromboembolism --- thrombosis --- pulmonary embolism --- neoplasms --- anticoagulants --- coumarins --- low molecular weight heparins --- cancer --- endogenous heparin --- heparanase --- heparan sulfate --- hospice --- palliative care units --- low molecular weight heparin --- deep vein thrombosis --- cancer associated thrombosis --- VTE --- malignancy --- direct oral anticoagulant --- pancreatic cancer --- low-molecular weight heparin --- survival --- coagulation activation --- locally advanced breast cancer --- prognostic model --- pCR --- treatment --- prophylaxis --- DOAC --- simultaneous care --- integrated care --- lymphoma --- Non-Hodgkin lymphoma --- Hodgkin lymphoma --- risk factors --- molecular subtype --- arterial thrombosis --- ALK --- ROS1 --- KRAS --- chemotherapy --- low-molecular-weight heparin (LMWH) --- VKA --- UFH --- DOACs --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Over recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to a better understanding of the genetic basis of lymphoma, identification of new therapeutic targets, and potentially valuable prognostic information. Monoclonal antibody therapies, radioimmunoconjugates and other new agents such as proteosome inhibitors are providing important new treatment options for patients. In this volume, an internationally recognized group of experts provides a comprehensive overview of the biology, pathology, standard treatments, and novel approaches in management of patients across the complex landscape of lymphoma subtypes. Researchers and practitioners alike will welcome this useful summary of the state of the art in this field.

Hodgkin's disease. --- Hodgkin disease --- Hodgkin lymphoma --- Hodgkin's lymphoma --- Lymphadenoma --- Lymphogranuloma --- Lymphogranulomatosis --- Lymphosarcoma --- Pseudoleucemia --- Lymphomas --- Oncology  . --- Hematology. --- Pathology. --- Interventional radiology. --- Oncology. --- Interventional Radiology. --- Radiology, Interventional --- Medical radiology --- Therapeutics --- Disease (Pathology) --- Medical sciences --- Diseases --- Medicine --- Medicine, Preventive --- Haematology --- Internal medicine --- Blood --- Tumors --- Interventional radiology .

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed.

Medicine --- Oncology --- multiple myeloma --- venous thromboembolism --- risk assessment models --- thromboprophylaxis --- direct oral anticoagulants --- cancer-associated venous thromboembolism --- thrombosis --- pulmonary embolism --- neoplasms --- anticoagulants --- coumarins --- low molecular weight heparins --- cancer --- endogenous heparin --- heparanase --- heparan sulfate --- hospice --- palliative care units --- low molecular weight heparin --- deep vein thrombosis --- cancer associated thrombosis --- VTE --- malignancy --- direct oral anticoagulant --- pancreatic cancer --- low-molecular weight heparin --- survival --- coagulation activation --- locally advanced breast cancer --- prognostic model --- pCR --- treatment --- prophylaxis --- DOAC --- simultaneous care --- integrated care --- lymphoma --- Non-Hodgkin lymphoma --- Hodgkin lymphoma --- risk factors --- molecular subtype --- arterial thrombosis --- ALK --- ROS1 --- KRAS --- chemotherapy --- low-molecular-weight heparin (LMWH) --- VKA --- UFH --- DOACs --- multiple myeloma --- venous thromboembolism --- risk assessment models --- thromboprophylaxis --- direct oral anticoagulants --- cancer-associated venous thromboembolism --- thrombosis --- pulmonary embolism --- neoplasms --- anticoagulants --- coumarins --- low molecular weight heparins --- cancer --- endogenous heparin --- heparanase --- heparan sulfate --- hospice --- palliative care units --- low molecular weight heparin --- deep vein thrombosis --- cancer associated thrombosis --- VTE --- malignancy --- direct oral anticoagulant --- pancreatic cancer --- low-molecular weight heparin --- survival --- coagulation activation --- locally advanced breast cancer --- prognostic model --- pCR --- treatment --- prophylaxis --- DOAC --- simultaneous care --- integrated care --- lymphoma --- Non-Hodgkin lymphoma --- Hodgkin lymphoma --- risk factors --- molecular subtype --- arterial thrombosis --- ALK --- ROS1 --- KRAS --- chemotherapy --- low-molecular-weight heparin (LMWH) --- VKA --- UFH --- DOACs